Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India Launch

▴ Chikungunya Vaccine
As Valneva works towards making this groundbreaking vaccine available in India, the collaboration with CEPI and Instituto Butantan underlines the global effort to address infectious diseases. The upcoming regulatory interactions with DCGI will shed light on the timeline for Ixchiq's launch in India.

In a significant stride against the mosquito-borne illness chikungunya, French biotech company Valneva has secured approval from the US Food and Drug Administration (USFDA) for its vaccine, Ixchiq. This marks a groundbreaking moment as it becomes the first licensed vaccine globally to combat this viral disease. The company now sets its sights on making this innovative vaccine available in India, with plans to collaborate with the Coalition for Epidemic Preparedness Innovations (CEPI) and Instituto Butantan in Brazil.

Ixchiq Approval and Global Impact: The USFDA's recent approval of Ixchiq targets individuals aged 18 and above at an increased risk of exposure to the chikungunya virus. This virus, primarily transmitted by the Aedes mosquito, poses a global health threat, with at least 5 million reported cases globally in the past 15 years. The disease, characterized by severe arthritis, fever, and rash, though rarely life-threatening, is debilitating and challenging to treat.

Valneva's Commitment to Accessibility: In response to inquiries about the vaccine's availability in India, Valneva's Chief Medical Officer, Juan Carlos Jaramillo, expressed the company's commitment to making Ixchiq accessible in the country. Through partnerships with CEPI and Instituto Butantan, an agreement signed in January 2021, the aim is to extend the availability of the chikungunya vaccine to low- and middle-income countries. However, specific details about the vaccine's distribution in India, whether through the government's Universal Immunization Programme or the private market, are yet to be finalized.

Regulatory Processes and Timelines: Jaramillo emphasized that the timeline for introducing Ixchiq in India would be determined after regulatory interactions with the Drugs Controller General of India (DCGI). While the company is diligently working with partners, decisions regarding distribution channels will factor in regulatory timelines and requirements.

Chikungunya in India: Chikungunya's resurgence in India in 2006 and its subsequent impact on public health have been notable. Data from the National Center for Vector Borne Diseases Control (NCVBDC) under the Union Health Ministry highlights a substantial number of suspected and confirmed cases since 2018. In 2022 alone, there were 1,48,587 suspected and 8,067 confirmed cases across the country.

The USFDA approval of Valneva's Ixchiq heralds a new chapter in the fight against chikungunya, offering hope for those at risk. As Valneva works towards making this groundbreaking vaccine available in India, the collaboration with CEPI and Instituto Butantan underlines the global effort to address infectious diseases. The upcoming regulatory interactions with DCGI will shed light on the timeline for Ixchiq's launch in India, marking a significant step in strengthening the nation's defences against chikungunya

Tags : #chikungunya #vaccine #USFDA #Valneva #CEPI #mosquitoborne #viralillness #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Exploring the Link Between Covid-19 Vaccination and Sudden Cardiac Arrests: ICMR StudyNovember 22, 2023
Powering the Future: China's Biodegradable Wireless System for Bioelectronic InnovationNovember 22, 2023
IMS BHU Pioneers Advanced Cardiac Care: Unveiling Cutting-Edge Technologies for Precise DiagnosisNovember 18, 2023
Inito's $6 Million Boost: Transforming Women's Health with AI-Backed Fertility MonitoringNovember 18, 2023
Madras High Court Advocates for Equality: PG Medical Students to Receive Incentive Marks for COVID-19 DutyNovember 18, 2023
Next-Gen Healthcare: CarePods and AI Redefine the Patient ExperienceNovember 17, 2023
Air Quality Crisis: Alarming Rise in Premature Births Linked to Air Quality in Begusarai, BiharNovember 17, 2023
Limerick Contest-2023: A Celebration of Wit and PoetryNovember 17, 2023
IIIT-Hyderabad among top 100 institutions for 5G Use Case LabNovember 17, 2023
Powerful, motivating and inspiring talks marked TEDx Hyderabad Women 2023 which was held with the theme "Two Steps ForwardNovember 17, 2023
Speaking the Diagnosis: How AI in Voice Analysis Is Revolutionizing Diabetes DetectionNovember 17, 2023
FDA Approves Zepbound: A New Medication for Weight Loss by Eli LillyNovember 17, 2023
CoverSelf Raises $8.2 Million in Seed Funding to Revolutionize Healthcare Claims with Innovative Fintech PlatformNovember 16, 2023
From Miracle to Medic: The Extraordinary Journey of India's First Paediatric Liver Transplant RecipientNovember 16, 2023
Combatting Chikungunya: Valneva's Chikungunya Vaccine Cleared by USFDA, Eyes India LaunchNovember 16, 2023
Global Corporate Summit 2023 with the theme Unlocking Opportunities in a Dynamic World heldNovember 16, 2023
2nd IHub-Data Mobility Summit heldNovember 16, 2023
Revolutionary AI-powered technology detects multiple abdominal pathologies simultaneouslyNovember 16, 2023
1 Out of 3 Stroke Patients Suffer Long-Term Health Complications, Says NeurologistNovember 16, 2023
Amrita Hospital, Kochi, Launches App for People with Swallowing DifficultiesNovember 15, 2023